Matthijs M Versteegh (M M Versteegh, Matthijs Versteegh)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 21

Top Topics

Polycyclic Aromatic Hydrocarbons

Cognitive Impairment

Metastatic Breast Cancer

Top Venues

Personalized medicine

Health economics

PharmacoEconomics

This page only lists publications with an associated author ORCID identifier.

Publications

Valérie J van Hezik-Wester, Saskia de Groot, Tim Kanters, Louis Wagner, Jacqueline Ardesch, Werner Brouwer, Isaac Corro Ramos, Saskia le Cessie, Matthijs M Versteegh, Job van Exel, null null
Effectiveness of Seizure Dogs for People With Severe Refractory Epilepsy: Results From the EPISODE Study. Neurology 102 (6) (2024)
Valérie J van Hezik-Wester, Saskia de Groot, Tim Kanters, Louis Wagner, Jacqueline Ardesch, Werner Brouwer, Isaac Corro Ramos, Saskia le Cessie, Matthijs M Versteegh, Job van Exel, null null
Effectiveness of Seizure Dogs for People With Severe Refractory Epilepsy: Results From the EPISODE Study. Neurology 102 (6) (2024)
Valérie J van Hezik-Wester, Saskia de Groot, Tim Kanters, Louis Wagner, Jacqueline Ardesch, Werner Brouwer, Isaac Corro Ramos, Saskia le Cessie, Matthijs M Versteegh, Job van Exel, null null
Effectiveness of Seizure Dogs for People With Severe Refractory Epilepsy: Results From the EPISODE Study. Neurology 102 (6) (2024)
Valérie J van Hezik-Wester, Saskia de Groot, Tim Kanters, Louis Wagner, Jacqueline Ardesch, Werner Brouwer, Isaac Corro Ramos, Saskia le Cessie, Matthijs M Versteegh, Job van Exel, null null
Effectiveness of Seizure Dogs for People With Severe Refractory Epilepsy: Results From the EPISODE Study. Neurology 102 (6) (2024)
Rositsa Koleva-Kolarova, Heleen Vellekoop, Simone A Huygens, Matthijs M Versteegh, Maureen P M H Rutten-van Mölken, László Szilberhorn, Tamás Zelei, Balázs Nagy, Sarah Wordsworth, Apostolos Tsiachristas
Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK. Personalized medicine (2023)
László Szilberhorn, Tamás Zelei, Heleen Vellekoop, Simone A Huygens, Matthijs M Versteegh, Maureen P M H Rutten-van Mölken, Rositsa Koleva-Kolarova, Apostolos Tsiachristas, Sarah Wordsworth, Balázs Nagy
Cost-effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries. Personalized medicine (2023)
Gábor Kovács, Dávid Nagy, László Szilberhorn, Tamás Zelei, Zsolt Gaál, Heleen Vellekoop, Simone A Huygens, Matthijs M Versteegh, Maureen P M H Rutten-van Mölken, Rositsa Koleva-Kolarova, Apostolos Tsiachristas, Sarah Wordsworth, Balázs Nagy
Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young. Personalized medicine (2023)
Balázs Nagy, Tamás Zelei, Heleen Vellekoop, Simone A Huygens, Matthijs M Versteegh, Maureen P M H Rutten-van Mölken, Rositsa Koleva-Kolarova, Apostolos Tsiachristas, Sarah Wordsworth, László Szilberhorn
Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies. Personalized medicine (2023)
Rositsa Koleva-Kolarova, László Szilberhorn, Tamás Zelei, Heleen Vellekoop, Balázs Nagy, Simone A Huygens, Matthijs M Versteegh, Maureen P M H Rutten-van Mölken, Sarah Wordsworth, Apostolos Tsiachristas
Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation. Personalized medicine (2023)
Bram Wouterse, Pieter van Baal, Matthijs M Versteegh, Werner B F Brouwer
The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice. PharmacoEconomics (2023)
Heleen Vellekoop, Simone A Huygens, Matthijs M Versteegh, László Szilberhorn, Tamás Zelei, Balázs Nagy, Rositsa Koleva-Kolarova, Sarah Wordsworth, Maureen P M H Rutten-van Mölken, null null
Cost-effectiveness of alternative NTRK testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countries. Personalized medicine (2023)
Rositsa Koleva-Kolarova, Heleen Vellekoop, Simone A Huygens, Matthijs M Versteegh, Maureen P M H Rutten-van Mölken, László Szilberhorn, Tamás Zelei, Balázs Nagy, Sarah Wordsworth, Apostolos Tsiachristas
Budget impact and transferability of cost-effectiveness of DPYD testing in metastatic breast cancer in three health systems. Personalized medicine (2023)
Irene Santi, Andrew J Lloyd, Claudia E Hastedt, Matthijs M Versteegh
Societal Utilities for Cognitive Impairment in Schizophrenia: Developing a Preference-Based Scoring Algorithm Based on the Schizophrenia Cognition Rating Scale. Advances in therapy (2023)
Maureen P M H Rutten-van Mölken, Matthijs M Versteegh, Balázs Nagy, Sarah Wordsworth
HEcoPerMed, personalized medicine from a health economic perspective: lessons learned and potential opportunities ahead. Personalized medicine (2023)
Tobias B Polak, David G J Cucchi, Jonathan J Darrow, Matthijs M Versteegh
Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020. BMJ open 12 (4) (2022)
Stefan Adriaan Lipman, Arthur E Attema, Matthijs M Versteegh
Correcting for discounting and loss aversion in composite time trade-off. Health economics 31 (8) (2022)
Heleen Vellekoop, Simone A Huygens, Matthijs M Versteegh, László Szilberhorn, Tamás Zelei, Balázs Nagy, Rositsa Koleva-Kolarova, Apostolos Tsiachristas, Sarah Wordsworth, Maureen P M H Rutten-van Mölken, null null
Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine. PharmacoEconomics 39 (7) (2021)
Frédérique C W van Krugten, Jan J V Busschbach, Matthijs M Versteegh, Leona Hakkaart van Roijen, Werner B F Brouwer
The Mental Health Quality of Life Questionnaire (MHQoL): development and first psychometric evaluation of a new measure to assess quality of life in people with mental health problems. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2021)
Klas Kellerborg, Werner Brouwer, Matthijs M Versteegh, Bram Wouterse, Pieter van Baal
Distributional consequences of including survivor costs in economic evaluations. Health economics 30 (10) (2021)
Matthijs M Versteegh, Isaac Corro Ramos, Nasuh C Buyukkaramikli, Amir Ansaripour, Vivian T Reckers-Droog, Werner B F Brouwer
Severity-Adjusted Probability of Being Cost Effective. PharmacoEconomics 37 (9) (2020)
Pieter van Baal, Meg Perry-Duxbury, Pieter L H Bakx, Matthijs M Versteegh, Eddy van Doorslaer, Werner Brouwer
A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending. Health economics 28 (1) (2018)